EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 71 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Impressive Responses to PD-1 Blockade in a Large Cohort of Children... January 17, 2022 Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... May 19, 2023 FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Load more HOT NEWS Forging Military Partnerships to Empower the Cancer Research Enterprise For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment Cancer Surgery Unexpectedly Canceled for Mother of Two, Who Says It’s... Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer
